|
Phase II study of docetaxel-prednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) ...... |
95.00% |
|
The PEP-C regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy. |
90.00% |
|
Cellular immune suppression in cancer patients and its implication for dendritic cell therapy. Sub-category: Cell-Based Therapy |
90.00% |
|
Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs. |
90.00% |
|
A randomized trial of personalized peptide vaccine (PPV) plus low-dose estramustine (EMP) versus full-dose EMP in patients ..... |
90.00% |
|
Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. |
90.00% |
|
Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. |
90.00% |
|
Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potent |
90.00% |
|
Why are tumour blood vessels abnormal and why is it important to know? |
90.00% |
|
Metronomic schedule of temozolomide with conventional dose of cisplatin in metastatic melanoma. Sub-category: Melanoma Categor |
90.00% |
|
Antiangiogenic metronomic chemotherapy and hyperthermia in the palliation of advanced cancer. |
90.00% |
|
Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor acti |
90.00% |
|
Metronomic chemotherapy: changing the paradigm that more is better. |
90.00% |
|
Low dose "Metronomic" Chemotherapy |
89.00% |
|
Systems biology: a therapeutic target for tumor therapy. |
86.67% |
|
The anti-angiogenic basis of metronomic chemotherapy. |
85.00% |
|
Inhibitory effect of ginsenoside Rg3 combined with cyclophosphamide on growth and angiogenesis of ovarian cancer. |
80.00% |
|
Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. |
80.00% |
|
Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. |
80.00% |
|
Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patient |
80.00% |
|
Metronomic chemotherapy using weekly low-dosage CPT-11 and UFT as postoperative adjuvant therapy in colorectal cancer at high... |
80.00% |
|
Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glio |
80.00% |
|
Metronomic Schedule of Paclitaxel Is Effective in Hormone Receptor–Positive and Hormone Receptor–Negative Breast Cancer |
80.00% |
|
Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide, Celecoxib, and Dexamethasone in Advanced Hormone-refract |
80.00% |
|
Metronomic antiangiogenetic biochemotherapy of non-small cell lung cancer patients .... |
80.00% |
|
Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. |
80.00% |
|
Hyperthermia improves the antitumour effect of metronomic cyclophosphamide in a rat transplantable brain tumour. |
80.00% |
|
Biweekly oxaliplatin plus 1-day infusional fluorouracil/leucovorin followed by metronomic chemotherapy with tegafur/uracil in--- |
80.00% |
|
Different metronomic treatment schedules |
80.00% |
|
The emerging low-dose therapy for advanced cancers. |
80.00% |
|
Activity of a multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen in metastatic renal cell carcinoma (m |
80.00% |
|
A phase II study of sorafenib in combination with tegafur/uracil (UFT) for Asian patients with advanced hepatocellular carcinoma |
80.00% |
|
Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast ca |
80.00% |
|
The effect of whole-body hyperthermia combined with 'metronomic' chemotherapy on rat mammary adenocarcinoma metastases. |
80.00% |
|
To widen the setting of cancer patients who could benefit from metronomic capecitabine. |
80.00% |
|
Effective treatment of advanced human melanoma metastasis in immunodeficient mice using combination metronomic chemotherapy regi |
80.00% |
|
Impressive survival data with semimetronomic oral chemotherapy with old agents in heavily treated metastatic breast cancer..... |
75.00% |
|
Durable responses with the antiangiogenic metronomic regimen RT-PEPC in elderly patients with recurrent mantle cell lymphoma |
70.00% |
|
Clinical-translational strategies for the elevation of Nm23-H1 metastasis suppressor gene expression. |
70.00% |
|
Antiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectives. |
70.00% |
|
Randomized phase II trial of capecitabine versus capecitabine, low molecular weight heparin, and prednisone in refractory....... |
70.00% |
|
Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a stu |
70.00% |
|
PPAR gamma agonists can be expected to potentiate the efficacy of metronomic chemotherapy through CD36 up-regulation. |
70.00% |
|
High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and re |
70.00% |
|
A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses |
70.00% |
|
Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer |
70.00% |
|
Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "do ut des" paradigm). |
70.00% |
|
Randomized phase II clinical trial of chemo-immunotherapy in advanced nonsmall cell lung cancer. |
70.00% |
|
Low-dose metronomic cyclophosphamide treatment mediates ischemia-dependent K-ras mutation in colorectal carcinoma xenografts. |
70.00% |
|
Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic bre |
70.00% |
|
Effect of metronomic use of zoledronic acid (ZOL) on antitumor and antiosteoclastic effects in breast cancer patients with bone |
70.00% |
|
Oral metronomic cyclophosphamide in elderly with metastatic melanoma. |
70.00% |
|
Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model. |
70.00% |
|
Phase II trial of pharmacodynamically (PDally)-guided optimal biologic dose titration (OBDT) of sorafenib (S) in combination wit |
70.00% |
|
Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity. |
70.00% |
|
Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide r |
70.00% |
|
Dose-Dense and/or Metronomic Schedules of Specific Chemotherapies Consolidate the Chemosensitivity of Triple-Negative Breast Can |
63.33% |
|
Tumor pO(2) as a Surrogate Marker to Identify Therapeutic Window during Metronomic Chemotherapy of 9L Gliomas. |
60.00% |
|
Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer with metronomic UFT + CP |
60.00% |
|
CECs, CEPs and CTCs for prediction of response in patients with advanced breast cancer (ABC) receiving metronomic vinorelbine. |
60.00% |
|
A case of metronomic chemotherapy as an alternative cancer therapy for palliation |
60.00% |
|
Low-dose methotrexate and cyclophosphamide in recurrent ovarian cancer. |
60.00% |
|
Antiangiogenic drugs currently used for colorectal cancer: what other pathways can we target to prolong responses? |
60.00% |
|
Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase. |
60.00% |
|
Significance of thymidine phosphorylase in metronomic chemotherapy using CPT-11 and doxifluridine for advanced colorectal...... |
60.00% |
|
SWOG 0012, a randomized phase III comparison of standard doxorubicin (A) and cyclophosphamide (C) followed by weekly paclitaxel |
60.00% |
|
Metronomic administration of ibandronate and its anti-angiogenic effects in vitro. |
60.00% |
|
Dose-Ranging Study of Metronomic Oral Vinorelbine in Patients with Advanced Refractory Cancer. |
60.00% |
|
Oral methotrexate for recurrent brain tumors in children: a Pediatric Oncology Group study. |
60.00% |
|
Low dose carboplatin combined with angiostatic agents prevents metastasis in human testicular germ cell tumor xenografts. |
55.00% |
|
A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin.... |
50.00% |
|
Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. |
50.00% |
|
Inhibition of angiogenesis by non-toxic doses of temozolomide. |
50.00% |
|
Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy |
50.00% |
|
Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. |
50.00% |
|
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. |
50.00% |
|
Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofe |
50.00% |
|
A phase II trial of thalidomide plus tegafur/uracil for patients with advanced/metastatic hepatocellular carcinoma (HCC) |
50.00% |
|
Tumoral angiogenesis: review of the literature. |
50.00% |
|
Preclinical antitumor and antiangiogenic activity of a metronomic schedule of cisplatin against human transitional cell carcinom |
50.00% |
|
A novel metronomic schedule of oral vinorelbine for the treatment of metastatic breast cancer in elderly patients............... |
50.00% |
|
A phase I study of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer. |
40.00% |
|
Anti-angiogenic effect of 5-Fluorouracil-based drugs against human colon cancer xenografts. |
40.00% |
|
Control of cancer-associated inflammation and survival: Results from a prospective randomized phase II trial in gastric cancer. |
40.00% |
|
Kinetics study on markers of the immune system by gene expression profiling of an in vivo heated tumor. |
40.00% |
|
Outpatient administration of high-dose methotrexate for osteosarcoma treatment in Brazil. |
30.00% |
|
Oral metronomic chemotherapy using cyclophosphamide in metastatic patients (pts) after standard treatment: Results of a randomiz |
25.00% |
|
A pilot study of adjuvant bevacizumab and chemotherapy after neoadjuvant chemotherapy for high-risk breast cancer. |
|
